The Maudsley prescribing guidelines in psychiatry / David M. Taylor, Thomas R. E. Barnes, Allan H. Young.

By: Taylor, David, 1963- [author.]
Contributor(s): Barnes, Thomas R. E [author.] | Young, A. H. (Allan H.) [author.]
Publisher: Hoboken, NJ : Wiley, 2018Edition: 13th editionDescription: xviii, 854 pages : illustrationsContent type: text Media type: unmediated Carrier type: volumeISBN: 9781119442608; 1119442605Other title: Prescribing guidelines in psychiatrySubject(s): Mental Disorders -- drug therapy | Psychotropic Drugs -- therapeutic use | Psychotropic Drugs -- administration & dosage | Psychopharmacology -- methods | Mental illness -- Treatment -- Great Britain | Psychopharmacology -- Great Britain | Psychotropic drugs -- Administration -- Great Britain | Psychotropic drugs -- Therapeutic use -- Great Britain | Mental illness -- Chemotherapy | Psychotropic drugs -- Administration | Psychotropic drugs -- Therapeutic useAdditional physical formats: Online version: Maudsley prescribing guidelines in psychiatry.DDC classification: 616.89/18 LOC classification: RC483
Contents:
Machine generated contents note: ch. 1 Schizophrenia and related psychoses -- Antipsychotic Drugs -- General introduction -- General principles of prescribing -- Minimuth effective doses -- Licensed maximum doses -- Equivalent doses -- High-dose antipsychotics: prescribing and monitoring -- Combined antipsychotics -- Antipsychotic prophylaxis -- Negative symptoms -- Monitoring -- Relative adverse effects - a rough guide -- Treatment algorithms for schizophrenia -- First-generation antipsychotics - place in therapy -- NICE guidelines for the treatment of schizophrenia -- Antipsychotic response - to increase the dose, to switch, to add or just wait - what is the right move? -- Acutely disturbed or violent behaviour -- Antipsychotic depots/long-acting injections (LAIs) -- Depot/LAI antipsychotics - pharmacokinetics -- Management of patients on long-term depots/LAIs -- Aripiprazole long-acting injection -- Olanzapine long-acting injection --
Contents note continued: Paliperidone palmitate long-acting injection -- Risperidone long-acting injection -- Electroconvulsive therapy and psychosis -- Omega-3 fatty acid (fish oils) in schizophrenia -- Antipsychotic Adverse Effects -- Extrapyramidal symptoms -- Akathisia -- Weight gain -- Treatment of antipsychotic-induced weight gain -- Neuroleptic malignant syndrome -- Catatonia -- ECG changes - QT prolongation -- Effect of antipsychotic medications on plasma lipids -- Diabetes and impaired glucose tolerance -- Blood pressure changes -- Hyponatraemia -- Hyperprolactinaemia -- Sexual dysfunction -- Pneumonia -- Switching antipsychotics -- Venous thromboembolism -- Refractory Schizophrenia And Clozapine -- Clozapine initiation schedule -- Optimising clozapine treatment -- Alternatives to clozapine -- Re-starting clozapine after a break in treatment -- Initiation of clozapine for community-based patients -- Clozapine Adverse Effects -- Clozapine: common adverse effects --
Contents note continued: Clozapine: uncommon or unusual adverse effects -- Clozapine: serious haematological and cardiovascular adverse effects -- Clozapine-induced hypersalivation -- Clozapine-induced gastrointestinal hypomotility (CIGH) -- Clozapine, neutropenia and lithium -- Clozapine and chemotherapy -- ch. 2 Bipolar disorder -- Lithium -- Valproate -- Carbamazepine -- Antipsychotic drugs in bipolar disorder -- Antipsychotic long-acting injections in bipolar disorder -- Physical monitoring for people with bipolar disorder -- Treatment of acute mania or hypomania -- Rapid-cycling bipolar disorder -- Bipolar depression -- Prophylaxis in bipolar disorder -- ch. 3 Depression and anxiety disorders -- Depression: introduction -- Basic principles of prescribing in depression -- Official guidance on the treatment of depression -- Antidepressants: general overview -- Recognised minimum effective doses of antidepressants -- Drug treatment of depression --
Contents note continued: Treatment of refractory depression: first choice -- Treatment of refractory depression: second choice -- Treatment of refractory depression: other reported treatments -- Psychotic depression -- Electroconvulsive therapy and psychotropic drugs -- Stimulants in depression -- Post-stroke depression -- Treatment of depression in the elderly -- Antidepressants: alternative routes of administration -- Antidepressant prophylaxis -- Antidepressant discontinuation symptoms -- Antidepressants: swapping and stopping -- Drug interactions with antidepressants -- Cardiac effects of antidepressants -- Antidepressant-induced arrhythmia -- Antidepressant-induced hyponatraemia -- Antidepressants and hyperprolactinaemia -- Antidepressants and diabetes mellitus -- Antidepressants and sexual dysfunction -- SSRIs and bleeding -- St John's wort -- Antidepressants: relative adverse effects - a rough guide -- Anxiety spectrum disorders --
Contents note continued: Benzodiazepines in the treatment of psychiatric disorders -- Benzodiazepines: dependence and detoxification -- Benzodiazepines and disinhibition -- ch. 4 Addictions and substance misuse -- Introduction -- Alcohol dependence -- Opioid dependence -- Nicotine and smoking cessation -- Pharmacological treatment of dependence on stimulants -- GHB and GBL dependence -- Benzodiazepine misuse -- Synthetic cannabinoid receptor agonists (SCRAs) -- Interactions between 'street drugs' and prescribed psychotropic drugs -- Drugs of misuse - a summary -- ch. 5 Children and adolescents -- Principles of prescribing practice in childhood and adolescence -- Depression in children and adolescents -- Bipolar illness in children and adolescents -- Psychosis in children and adolescents -- Anxiety disorders in children and adolescents -- Obsessive compulsive disorder (OCD) in children and adolescents -- Post-traumatic stress disorder in children and adolescents --
Contents note continued: Attention deficit hyperactivity disorder -- Autism spectrum disorder -- Tics and Tourette's syndrome -- Melatonin in the treatment of insomnia in children and adolescents -- Rapid tranquillisation (RT) in children and adolescents -- Doses of commonly used psychotropic drugs in children and adolescents -- ch. 6 Prescribing in older people -- General principles -- Dementia -- Safer prescribing for physical conditions in dementia -- Management of behavioural and psychological symptoms of dementia -- A guide to medication doses of commonly used psychotropic drugs in older adults -- Covert administration of medicines within food and drink -- ch. 7 Pregnancy and breastfeeding -- Drug choice in pregnancy -- Breastfeeding -- ch. 8 Hepatic and renal impairment -- Hepatic impairment -- Renal impairment -- ch. 9 Drug treatment of other psychiatric conditions -- Borderline personality disorder -- Eating disorders -- Delirium --
Contents note continued: ch. 10 Drug treatment of psychiatric symptoms occurring in the context of other disorders -- General principles of prescribing in human immunodeficiency virus (HIV) -- Prescribing psychotropics in HIV -- Epilepsy -- 22q11.2 Deletion syndrome -- Learning disabilities -- Huntington's disease -- Multiple sclerosis -- Parkinson's disease -- Atrial fibrillation -- Bariatric surgery -- ch. 11 Pharmacokinetics -- Plasma level monitoring of psychotropic drugs -- Interpreting post-mortem blood concentrations -- Acting on clozapine plasma concentration results -- Psychotropic drugs and cytochrome (CYP) function -- Smoking and psychotropic drugs -- Drug interactions with alcohol -- ch. 12 Other substances -- Caffeine -- Nicotine -- ch. 13 Psychotropic drugs in special conditions -- Psychotropic drugs in overdose -- Driving and psychotropic drugs -- Psychotropic drugs and surgery -- ch. 14 Miscellany -- Enhancing medication adherence --
Contents note continued: Re-starting psychotropic medications after a period of non-compliance -- Biochemical and haematological effects of psychotropic medications -- Summary of psychiatric adverse effects of non-psychotropic medications -- Prescribing drugs outside their licensed indications ('off-label' prescribing) -- The Mental Health Act in England and Wales -- Site of administration of intramuscular injections.
Summary: The revised and updated 13th edition of The Maudsley Prescribing Guidelines in Psychiatry provides up-to-date, expert guidance on prescribing practice in mental health, including drug choice, treatment of adverse effects and how to augment or switch medications. The text covers a wide range of topics including pharmacological interventions for schizophrenia, bipolar disorder, depression and anxiety, and many other less common conditions. There is advice on prescribing in children and adolescents, in substance misuse and in special patient groups. --Summary: This world-renowned guide has been written in concise terms by an expert team of psychiatrists and specialist pharmacists. The Guidelines help with complex prescribing problems and include information on prescribing psychotropic medications outside their licensed indications as well as potential interactions with other medications and substances such as alcohol, tobacco and caffeine. In addition, each of the book's sections features a full reference list so the evidence on which guidance is based can be readily accessed. This important text: --Summary: Is the world's leading clinical resource for evidence-based prescribing in day-to-day clinical practice and for formulating prescribing policy --Summary: Includes referenced information on topics such as transferring from one medication to another, prescribing psychotropic medications during pregnancy or breastfeeding, and treating patients with comorbid physical conditions, including impaired renal or hepatic function --Summary: Presents guidance on complex clinical problems that may not be encountered routinely --Book Jacket.
List(s) this item appears in: Medications, pharmaceutical and psychopharmacology | Psychiatry
Item type Current library Collection Call number Status Date due Barcode Item holds
Book Book Cairns Hospital Library & Knowledge Centre

Library & Knowledge Centre
L2, A-Block, Cairns Hospital
Esplanade
CAIRNS  QLD  4870
(07) 422 66679
cairns_library@health.qld.gov.au
https://cairns.health.qld.libguides.com/lkc-home

General Collection
General Collection 616.8918 TAY 2018 (Browse shelf (Opens below)) Available m29684w4870
Total holds: 0

Includes bibliographical references and index.

Machine generated contents note: ch. 1 Schizophrenia and related psychoses -- Antipsychotic Drugs -- General introduction -- General principles of prescribing -- Minimuth effective doses -- Licensed maximum doses -- Equivalent doses -- High-dose antipsychotics: prescribing and monitoring -- Combined antipsychotics -- Antipsychotic prophylaxis -- Negative symptoms -- Monitoring -- Relative adverse effects - a rough guide -- Treatment algorithms for schizophrenia -- First-generation antipsychotics - place in therapy -- NICE guidelines for the treatment of schizophrenia -- Antipsychotic response - to increase the dose, to switch, to add or just wait - what is the right move? -- Acutely disturbed or violent behaviour -- Antipsychotic depots/long-acting injections (LAIs) -- Depot/LAI antipsychotics - pharmacokinetics -- Management of patients on long-term depots/LAIs -- Aripiprazole long-acting injection -- Olanzapine long-acting injection --

Contents note continued: Paliperidone palmitate long-acting injection -- Risperidone long-acting injection -- Electroconvulsive therapy and psychosis -- Omega-3 fatty acid (fish oils) in schizophrenia -- Antipsychotic Adverse Effects -- Extrapyramidal symptoms -- Akathisia -- Weight gain -- Treatment of antipsychotic-induced weight gain -- Neuroleptic malignant syndrome -- Catatonia -- ECG changes - QT prolongation -- Effect of antipsychotic medications on plasma lipids -- Diabetes and impaired glucose tolerance -- Blood pressure changes -- Hyponatraemia -- Hyperprolactinaemia -- Sexual dysfunction -- Pneumonia -- Switching antipsychotics -- Venous thromboembolism -- Refractory Schizophrenia And Clozapine -- Clozapine initiation schedule -- Optimising clozapine treatment -- Alternatives to clozapine -- Re-starting clozapine after a break in treatment -- Initiation of clozapine for community-based patients -- Clozapine Adverse Effects -- Clozapine: common adverse effects --

Contents note continued: Clozapine: uncommon or unusual adverse effects -- Clozapine: serious haematological and cardiovascular adverse effects -- Clozapine-induced hypersalivation -- Clozapine-induced gastrointestinal hypomotility (CIGH) -- Clozapine, neutropenia and lithium -- Clozapine and chemotherapy -- ch. 2 Bipolar disorder -- Lithium -- Valproate -- Carbamazepine -- Antipsychotic drugs in bipolar disorder -- Antipsychotic long-acting injections in bipolar disorder -- Physical monitoring for people with bipolar disorder -- Treatment of acute mania or hypomania -- Rapid-cycling bipolar disorder -- Bipolar depression -- Prophylaxis in bipolar disorder -- ch. 3 Depression and anxiety disorders -- Depression: introduction -- Basic principles of prescribing in depression -- Official guidance on the treatment of depression -- Antidepressants: general overview -- Recognised minimum effective doses of antidepressants -- Drug treatment of depression --

Contents note continued: Treatment of refractory depression: first choice -- Treatment of refractory depression: second choice -- Treatment of refractory depression: other reported treatments -- Psychotic depression -- Electroconvulsive therapy and psychotropic drugs -- Stimulants in depression -- Post-stroke depression -- Treatment of depression in the elderly -- Antidepressants: alternative routes of administration -- Antidepressant prophylaxis -- Antidepressant discontinuation symptoms -- Antidepressants: swapping and stopping -- Drug interactions with antidepressants -- Cardiac effects of antidepressants -- Antidepressant-induced arrhythmia -- Antidepressant-induced hyponatraemia -- Antidepressants and hyperprolactinaemia -- Antidepressants and diabetes mellitus -- Antidepressants and sexual dysfunction -- SSRIs and bleeding -- St John's wort -- Antidepressants: relative adverse effects - a rough guide -- Anxiety spectrum disorders --

Contents note continued: Benzodiazepines in the treatment of psychiatric disorders -- Benzodiazepines: dependence and detoxification -- Benzodiazepines and disinhibition -- ch. 4 Addictions and substance misuse -- Introduction -- Alcohol dependence -- Opioid dependence -- Nicotine and smoking cessation -- Pharmacological treatment of dependence on stimulants -- GHB and GBL dependence -- Benzodiazepine misuse -- Synthetic cannabinoid receptor agonists (SCRAs) -- Interactions between 'street drugs' and prescribed psychotropic drugs -- Drugs of misuse - a summary -- ch. 5 Children and adolescents -- Principles of prescribing practice in childhood and adolescence -- Depression in children and adolescents -- Bipolar illness in children and adolescents -- Psychosis in children and adolescents -- Anxiety disorders in children and adolescents -- Obsessive compulsive disorder (OCD) in children and adolescents -- Post-traumatic stress disorder in children and adolescents --

Contents note continued: Attention deficit hyperactivity disorder -- Autism spectrum disorder -- Tics and Tourette's syndrome -- Melatonin in the treatment of insomnia in children and adolescents -- Rapid tranquillisation (RT) in children and adolescents -- Doses of commonly used psychotropic drugs in children and adolescents -- ch. 6 Prescribing in older people -- General principles -- Dementia -- Safer prescribing for physical conditions in dementia -- Management of behavioural and psychological symptoms of dementia -- A guide to medication doses of commonly used psychotropic drugs in older adults -- Covert administration of medicines within food and drink -- ch. 7 Pregnancy and breastfeeding -- Drug choice in pregnancy -- Breastfeeding -- ch. 8 Hepatic and renal impairment -- Hepatic impairment -- Renal impairment -- ch. 9 Drug treatment of other psychiatric conditions -- Borderline personality disorder -- Eating disorders -- Delirium --

Contents note continued: ch. 10 Drug treatment of psychiatric symptoms occurring in the context of other disorders -- General principles of prescribing in human immunodeficiency virus (HIV) -- Prescribing psychotropics in HIV -- Epilepsy -- 22q11.2 Deletion syndrome -- Learning disabilities -- Huntington's disease -- Multiple sclerosis -- Parkinson's disease -- Atrial fibrillation -- Bariatric surgery -- ch. 11 Pharmacokinetics -- Plasma level monitoring of psychotropic drugs -- Interpreting post-mortem blood concentrations -- Acting on clozapine plasma concentration results -- Psychotropic drugs and cytochrome (CYP) function -- Smoking and psychotropic drugs -- Drug interactions with alcohol -- ch. 12 Other substances -- Caffeine -- Nicotine -- ch. 13 Psychotropic drugs in special conditions -- Psychotropic drugs in overdose -- Driving and psychotropic drugs -- Psychotropic drugs and surgery -- ch. 14 Miscellany -- Enhancing medication adherence --

Contents note continued: Re-starting psychotropic medications after a period of non-compliance -- Biochemical and haematological effects of psychotropic medications -- Summary of psychiatric adverse effects of non-psychotropic medications -- Prescribing drugs outside their licensed indications ('off-label' prescribing) -- The Mental Health Act in England and Wales -- Site of administration of intramuscular injections.

The revised and updated 13th edition of The Maudsley Prescribing Guidelines in Psychiatry provides up-to-date, expert guidance on prescribing practice in mental health, including drug choice, treatment of adverse effects and how to augment or switch medications. The text covers a wide range of topics including pharmacological interventions for schizophrenia, bipolar disorder, depression and anxiety, and many other less common conditions. There is advice on prescribing in children and adolescents, in substance misuse and in special patient groups. --

This world-renowned guide has been written in concise terms by an expert team of psychiatrists and specialist pharmacists. The Guidelines help with complex prescribing problems and include information on prescribing psychotropic medications outside their licensed indications as well as potential interactions with other medications and substances such as alcohol, tobacco and caffeine. In addition, each of the book's sections features a full reference list so the evidence on which guidance is based can be readily accessed. This important text: --

Is the world's leading clinical resource for evidence-based prescribing in day-to-day clinical practice and for formulating prescribing policy --

Includes referenced information on topics such as transferring from one medication to another, prescribing psychotropic medications during pregnancy or breastfeeding, and treating patients with comorbid physical conditions, including impaired renal or hepatic function --

Presents guidance on complex clinical problems that may not be encountered routinely --Book Jacket.

Hosted by Prosentient